Brought to you by

Evofem raises $20mm through private placement concurrent with Neothetics merger
20 Oct 2017
Executive Summary
Concurrent with its merger with Neothetics Inc., Evofem Biosciences Inc. (the surviving company) brought in $20mm through a private placement of 9.7mm Neothetics common shares to Invesco Asset Management, which also received purchase warrants for 159mm Evofem common shares. In a separate transaction, the two firms announced they'd combine in a reverse stock swap to create a women's health-focused company. Proceeds from this financing will help support development of Evofem's lead candidate, the Phase III Amphora (L-lactic acid, citric acid, and potassium bitartrate), hormone-free, on-demand vaginal contraceptive gel.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com